Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 365

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 365
---
 population aging. Globally, the population of people aged 65 and over is growing
faster than all other age groups. We believe this trend will continue and anticipate increased demand for longevity-related
products and services. By focusing our business model exclusively in this field, we believe that we will be strategically positioned to
capitalize on this trend.

Clinical pipeline that
includes patented treatments

Through our initial
Target Acquisitions, we have established a portfolio of product candidates. Our LBI-201 Aureva Pulse product candidate currently
has a cleared IDE to conduct a Phase 3 clinical study. In addition, our LBI-101 product candidate for soft tissue reconstruction and repair
has completed enrollment in Phase 2 clinical investigation and the one-year follow-up period will conclude prior to the end of 2024. Our
LBI-001 Reflow RVO product candidate has a cleared IDE to conduct a Phase 2 clinical study. Each of these product candidates
currently has patent protection and provides us with an attractive portfolio of advanced clinical-stage assets.

Limited capital investments
needed to reach significant, near-term development milestone

We anticipate
the estimated funding requirement to complete our LBI-201 Aureva Pulse Phase 3 clinical study is approximately $7.4 million.
The estimated funding requirement to complete the Phase 3 clinical study for our LBI-101 product candidate for soft tissue reconstruction
and repair is approximately $6.5 million. The estimated funding needed to complete the LBI-001 Reflow RVO Phase 2 clinical
study is approximately $2.8 million. Collectively, we believe these near-term development milestones can be achieved with relatively modest
capital investment.

Collaboration with experienced
development partners

We have the benefit
of working with strong development partners in the advancement of our product candidates. Through our association with Johns Hopkins University,
our LBI-101 Phase 2 study for soft tissue reconstruction and repair received grant funding through the US Department of Defense. In addition,
we work with leading academic and research institutions around the world and have assembled a group of renowned experts in the fields
of ophthalmology, soft tissue repair and reconstruction and stroke to serve as our scientific and medical advisors. Combined, these resources
provide us with skilled and experienced network of development and advisory partners.

Experienced management
team with focus on bringing innovative technologies to market

Our management team has extensive experience in the development of medtech and biopharmaceutical products across
multiple therapeutic areas, including product design, formulation development, pre-cl